- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Diabetes
Lilly taking hard look at Pfizer's new Viagra strategy
May 6, 2013
Associated PressMajor drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.'s plan to sell Viagra directly
to consumers. The bold move blows up the drug industry's distribution model.
MoreMCDONALD: Groups making headway attacking health problems
April 6, 2013
Bob McDonaldThe statistics we hear so often are clear. As a community, we are not in an enviable place. We smoke more, exercise less and
weigh more than the national average, resulting in more diabetes than average.
MoreJ&J wins OK for first in new class of diabetes drugs
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
MoreLilly, Boehringer submit diabetes drug to FDA
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
MoreFDA probe of diabetes medications hurts drugmakers' stock
March 15, 2013
Bloomberg News, Associated PressShares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned
they are looking into potential risks of drugs in two classes of diabetes treatments.
MoreTestosterone for diabetes may be new market for Lilly, others
February 25, 2013
Bloomberg NewsResearchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of
diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
MoreLilly competitor gets backing on diabetes drug
January 10, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill
the company is seeking to make the first in a new family of drugs for managing blood sugar.
MoreLilly's insulin dip concerns analysts
October 29, 2012
J.K. WallEli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter
earnings report: Lilly’s insulin sales are down.
MoreRoche continues to restructure diabetes unit
October 22, 2012
J.K. WallRoche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified
number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
MoreLilly says experimental diabetes drug outperformed rivals
October 22, 2012
J.K. WallEli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical
trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
MoreLilly counting on diabetes products to challenge larger rivals
October 8, 2012
Bloomberg NewsEli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week
treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
MoreLilly competitor Novo investing $100M in China
September 24, 2012
Bloomberg NewsNovo Nordisk A/S, the world’s largest insulin maker, plans to spend $100 million on research in China. The move follows
a similar one by Indianapolis-based Eli Lilly, which opened a 150-person research center in Shanghai in May.
MoreLilly chases Novo in insulin race
June 11, 2012
J.K. WallEli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference
in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
MoreLilly: Forget Alzheimer's; think diabetes
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLilly to focus on cancer, diabetes in China, CEO says
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MoreBall State: Diabetes rising at alarming rate
December 12, 2011
J.K. WallIn 1993, only 3.8 percent of Hoosier adults had full-blown diabetes, compared with 9.8 percent today.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreGlucose monitor deal helps Roche catch up
November 7, 2011
J.K. WallRoche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless
handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the
day.
MoreLilly hid Zyprexa's diabetes risks, family’s lawyer argues
November 2, 2011
Bloomberg NewsEli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who
died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award
the family $40 million in compensatory damages.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreFDA gets new report on Lilly diabetes drug
September 12, 2011
Associated PressDrugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly
diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
MoreSponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Doug Henning!
These guy were thugs — they grew up in freaking Haughville! Smh, sigh. If the mayor needs/wants "quality" Black Hoosiers who are NOT corrupt, give me a call — I know plenty. Land bank info here - http://www.kubepharm.com/indylandbank/IndyLandBank.html
Magician and illusionist!
The basic idea of nice apartments with parking and retail is a good one, but this design seems overwhelmingly big/tall for Broad Ripple. The size could be disguised a bit with lots of big trees/landscaping, but the complex is too massive to blend in easily. That section of canal between College and Westfield will also need to be upgraded on both sides. Nice apartments facing onto a nice promenade with shade trees/plantings could bring together the canal towpath/Monon recreation, the outdoor seating at existing restaurants, and this project into something that upgrades the whole area. A plan for the whole stretch makes more sense than facing nice new housing onto what looks like a ditch. Is there a plan? Does the public have input? Who pays? The apartment idea seems to be reasonable, but Whole Foods is not a good idea for appropriate retail. Besides the store being physically too big, there are already Fresh Market at 54xCollege and Whole Foods in Nora for fancy groceries. Good Earth and Kroger are within walking distance of the Shell site. There are at least 7 grocery stores within a safe bike ride. Whole Foods would add nothing but traffic congestion. This design is on the right track, but there needs to be more work done to ensure that it blends in with and enhances the existing community. A project that large will set a tone for that whole part of town. It could be a real asset, but only if done right.
I did not move to Zionsville to live in Carmel. This and the subsequent developments to follow will ensure a vanilla uniformity of strip malls and apartment buildings as we seek to bring our town down to the least common denominator. We were warned before recent elections that pro-development council members would make sure their friends (landowners and developers) would be able to make their millions off of the exploitation of Zionsville. Why in God's name would we sell out the best preserved small town in the State of Indiana?